Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reversing The Downward Spiral Of Heart Failure

This article was originally published in Start Up

Executive Summary

Medtech start-ups are pioneering innovative device solutions that they hope will end the vicious cycle of costly hospitalizations and declining patient health. Profiles of BioVentrix, Calon-Cardio Technology, Cibiem, DC Devices, and LoneStar Heart.

You may also be interested in...

LoneStar Heart Inc.

LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.

DC Devices Inc.

DC Devices Inc. has developed the first transcatheter, permanent implant for treating heart failure with preserved ejection fraction. The implant, placed in the atrial septum, creates a small, controlled shunt, allowing blood to move from the higher-pressure left atrium to the lower pressure, more compliant right atrium; this serves to reduce left atrial pressure and relieve HF symptoms, without compromising cardiac output.

Cibiem Inc.

Cibiem Inc.’s catheter-based CBM system is designed to modulate the carotid body, a tiny group of chemoreceptors located at the fork of the carotid artery that helps regulate respiratory activity. The start-up believes its technology could mean new treatment possibilities for a broad range of diseases including heart failure, where it could address the remodeling that takes place as well as alleviate such symptoms as breathlessness.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts